NASDAQ Framework: Arrowhead Pharmaceuticals Inc.
Biopharmaceuticals, RNAi therapies, intractable diseases 1.
1: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. View Source
Arrowhead Pharmaceuticals, Inc., headquartered in Pasadena, California, is a biopharmaceutical company that develops medicines for the treatment of intractable diseases by silencing the genes that cause them. The company's pipeline includes several promising candidates such as Plozasiran, Zodasiran, and ARO-RAGE, which are in various stages of clinical trials targeting conditions like hypertriglyceridemia, mixed dyslipidemia, and asthma. Arrowhead collaborates with major pharmaceutical companies like Janssen, Takeda, and Amgen, and has recently presented significant preclinical and clinical data, indicating strong progress in its research and development efforts 23.
2: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. View Source3: Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA. View Source
UNKNOWN
The provided facts do not contain information about the current leadership or involvement of the founders of Arrowhead Pharmaceuticals Inc. 4.
The provided facts do not contain information about the current leadership or involvement of the founders of Arrowhead Pharmaceuticals Inc. 4.
4: Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA. View Source
MEDIUM RISK
Arrowhead Pharmaceuticals Inc. has shown promising developments in its pipeline with several candidates in various stages of clinical trials and collaborations with major pharmaceutical companies 5. However, the company reported a significant quarterly GAAP net loss of $125.3 million for the quarter ending March 31, compared to a net profit of $48.68 million the previous year 6. Additionally, the company's stock has experienced a substantial decline over the past three years, indicating potential unresolved challenges 7. While there is strong revenue growth and analyst support, the financial losses and stock performance suggest a medium risk level.
Arrowhead Pharmaceuticals Inc. has shown promising developments in its pipeline with several candidates in various stages of clinical trials and collaborations with major pharmaceutical companies 5. However, the company reported a significant quarterly GAAP net loss of $125.3 million for the quarter ending March 31, compared to a net profit of $48.68 million the previous year 6. Additionally, the company's stock has experienced a substantial decline over the past three years, indicating potential unresolved challenges 7. While there is strong revenue growth and analyst support, the financial losses and stock performance suggest a medium risk level.
5: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. View Source6: Based on Arrowhead Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $125.3 million. In comparison, last year the company earned a revenue of $146.27 million and had a net profit of $48.68 million View Source7: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders should be happy to see the share price up 13% in the last month. Meanwhile over the last three years the stock has dropped hard. Indeed, the share price is down a tragic 59% in the last three years. So the improvement may be a real relief to some. After all, could be that the fall was overdone. View Source
YES
Arrowhead Pharmaceuticals Inc. is advancing new product offerings, including Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial and presenting preclinical data on a new RNAi-based obesity program ARO-INHBE 8.
Arrowhead Pharmaceuticals Inc. is advancing new product offerings, including Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial and presenting preclinical data on a new RNAi-based obesity program ARO-INHBE 8.
8: Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial Business Wire Jun 25, 2024 5:55pm Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE Business Wire Jun 24, 2024 11:30am Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome Business Wire Jun 3, 2024 11:30am Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences Business Wire May 31, 2024 11:30am Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia Business Wire May 29, 2024 9:30am Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia Business Wire May 28, 2024 10:04am Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma Business Wire May 20, 2024 10:00am Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results Business Wire May 9, 2024 8:01pm Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma Business Wire May 2, 2024 8:01pm Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences Business Wire Apr 29, 2024 11:30am Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars Business Wire Apr 26, 2024 11:30am Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results Business Wire Apr 24, 2024 8:01pm Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease Business Wire Apr 24, 2024 11:30am View Source
Arrowhead Pharmaceuticals Inc. has a robust product roadmap and expansion strategy for 2024 through to 2026, focusing on advancing several key candidates through various stages of clinical trials. Notably, Plozasiran is set to enter the Phase 3 CAPITAN Cardiovascular Outcomes Trial, following successful topline results from the Phase 3 PALISADE Study for familial chylomicronemia syndrome 910. The company is also progressing with Zodasiran in Phase 2 trials for mixed hyperlipidemia 11, and ARO-RAGE, which has shown promising Phase 1/2a results for asthma 12. Additionally, Arrowhead is developing new programs such as ARO-INHBE, targeting obesity, with plans to seek regulatory clearance for clinical trials by late 2024 1314. These efforts are supported by collaborations with major pharmaceutical companies like Janssen, Takeda, and Amgen, indicating a strategic focus on expanding their RNAi-based therapeutic portfolio 15.
9: Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial Business Wire Jun 25, 2024 5:55pm Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE Business Wire Jun 24, 2024 11:30am Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome Business Wire Jun 3, 2024 11:30am Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences Business Wire May 31, 2024 11:30am Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia Business Wire May 29, 2024 9:30am Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia Business Wire May 28, 2024 10:04am Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma Business Wire May 20, 2024 10:00am Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results Business Wire May 9, 2024 8:01pm Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma Business Wire May 2, 2024 8:01pm Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences Business Wire Apr 29, 2024 11:30am Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars Business Wire Apr 26, 2024 11:30am Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results Business Wire Apr 24, 2024 8:01pm Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease Business Wire Apr 24, 2024 11:30am View Source10: Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome View Source11: Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia View Source12: Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma View Source13: Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE View Source14: The data showed ARO-INHBE significantly silenced the INHBE gene in the liver, potentially leading to reduced body weight gain, fat mass loss and preservation of lean mass. Arrowhead plans to seek regulatory clearance in late 2024 to begin clinical trials. View Source15: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. View Source